LUCENCE

LiquidHALLMARK® Patient Information

Simple. Swift. Sensitive.

Cancer and mutations

Cancer is a disease caused by genomic changes within cells of our body. These changes, called mutations, can be harmful, beneficial, or have no effect at all. Harmful mutations can cause normal cells to grow and divide uncontrollably, leading to cancer.

Genomic testing or tumor profiling can identify unique combinations of mutations within a patient's tumor. This information can be used to make clinical decisions on the best course of care for each patient.

How does genomic testing of tumor profiling help?

Genomic testing provides additional information to your provider that helps to personalize treatment according to your tumor's genomic profile. Based on the tumors mutation combination, test results can help your doctor identify which treatments are beneficial, as well as which may not be as effective.

Genomic testing results can also be used to match you to suitable clinical trials where new medicines are being developed. This may expand your treatment options considerably.

With treatment, tumor mutations can change. Genomic testing can be utilized to monitor these changes. Alterations with existing mutations and/or new mutations may be identified. This may provide additional information to further help personalize your treatment according to changes within your tumor's genomic profile.

When should I get a test?

To develop a personalized treatment plan from the start, testing is important at the time of diagnosis. However, testing is available at any point in your journey. Testing can also be utilized to monitor your response to treatment and/or changes within your tumor.

How can I get tested?

1. Talk to your doctor about getting tested. If appropriate, your doctor will order a genomic test for you.

2. A blood sample will be drawn within the doctors office and sent to Lucence for testing. At your convenience, your doctor can request a mobile phlebotomist to draw your blood in the comfort of your own home.

3. The blood sample is sent to Lucence for LiquidHALLMARK® which detects mutations specific to your cancer.

4. A personalized report is sent directly to your doctor within 7 working days.

5. Once reviewed, your doctor will contact you directly to discuss the results and the most suitable treatment options for you.

LUCENCE

LiquidHALLMARK enables personalized cancer care for you.

LiquidHALLMARK® is an ultra-sensitive liquid biopsy test that identifies tumor mutations or biomarkers circulating in the blood. It requires a single sample of blood.

By profiling the tumor and unique cancer LiquidHALLMARK® provides important information for cancer care and personalized treatment.

Is testing covered by insurance?

Coverage is dependent on many factors including your individual insurance policy, medical necessity, as well as other factors.

Does Lucence accept my insurance plan?

We welcome all insurance plans; including Commercial plans, Medicare, and Medicaid.

What if my insurance plan does not cover the entire cost of the test?

Lucence will NOT bill you for the difference between the billed amount and your insurance plan's allowed amount. The only costs you may be responsible for are deductibles or co-insurance payments decided by your insurance policy.



Patient Assistance Program

How do I apply for the Patient Financial Assistance Program? What happens next?

To enroll, simply sign the back of the test order form and choose how you prefer we communicate with you. If you have any out-of-pocket costs we will contact you to determine eligibility. Most applicants who qualify pay no more than $100.

Supporting you every step of the way

For questions or more information regarding your LiquidHALLMARK® test or billing, contact our Patient Excellence Team at 888-582-3623 or support.us@lucence.com. (Monday-Friday, 8:00am to 5:00pm PST).

Customer support: +1 888 LUCENCE (582-3623) support.us@lucence.com

lucence.com

Lucence Service Laboratory | 3520 W Bayshore Rd, Palo Alto, CA94303

Information for US medical professionals only

D 50414-LHI Rev A. 10 December 2021